Macrophage expression of active MMP-9 induces acute plaque disruption in apoE-deficient mice.

The majority of acute clinical manifestations of atherosclerosis are due to the physical rupture of advanced atherosclerotic plaques. It has been hypothesized that macrophages play a key role in inducing plaque rupture by secreting proteases that destroy the extracellular matrix that provides physical strength to the fibrous cap. Despite reports detailing the expression of multiple proteases by macrophages in rupture-prone regions, there is no direct proof that macrophage-mediated matrix degradation can induce plaque rupture. We aimed to test this hypothesis by retrovirally overexpressing the candidate enzyme MMP-9 in macrophages of advanced atherosclerotic lesions of apoE-/- mice. Despite a greater than 10-fold increase in the expression of MMP-9 by macrophages, there was only a minor increase in the incidence of plaque fissuring. Subsequent analysis revealed that macrophages secrete MMP-9 predominantly as a proform, and this form is unable to degrade the matrix component elastin. Expression of an autoactivating form of MMP-9 in macrophages in vitro greatly enhances elastin degradation and induces significant plaque disruption when overexpressed by macrophages in advanced atherosclerotic lesions of apoE-/- mice in vivo. These data show that enhanced macrophage proteolytic activity can induce acute plaque disruption and highlight MMP-9 as a potential therapeutic target for stabilizing rupture-prone plaques.

[1]  Jason L. Johnson,et al.  Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[2]  V. de Waard,et al.  Repopulation of Apolipoprotein E Knockout Mice With CCR2-Deficient Bone Marrow Progenitor Cells Does Not Inhibit Ongoing Atherosclerotic Lesion Development , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[3]  G. Angelini,et al.  Plaque Rupture After Short Periods of Fat Feeding in the Apolipoprotein E–Knockout Mouse: Model Characterization and Effects of Pravastatin Treatment , 2005, Circulation.

[4]  G. Opdenakker,et al.  In vivo activation of gelatinase B/MMP‐9 by trypsin in acute pancreatitis is a permissive factor in streptozotocin‐induced diabetes , 2004, The Journal of pathology.

[5]  S. Grässel,et al.  Pro-MMP-9 is a specific macrophage product and is activated by osteoarthritic chondrocytes via MMP-3 or a MT1-MMP/MMP-13 cascade. , 2004, Experimental cell research.

[6]  S. Hazen.  Myeloperoxidase and plaque vulnerability. , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[7]  D. Greaves,et al.  The role of chemokines in atherosclerosis: recent evidence from experimental models and population genetics , 2004, Current opinion in lipidology.

[8]  A. Luttun,et al.  Loss of Matrix Metalloproteinase-9 or Matrix Metalloproteinase-12 Protects Apolipoprotein E–Deficient Mice Against Atherosclerotic Media Destruction but Differentially Affects Plaque Growth , 2004, Circulation.

[9]  P. Dempsey,et al.  A Disintegrin and Metalloproteinase 10-Mediated Cleavage and Shedding Regulates the Cell Surface Expression of CXC Chemokine Ligand 16 , 2004, The Journal of Immunology.

[10]  B. Strandvik,et al.  Severe Hypercholesterolaemia Leads to Strong Th2 Responses to an Exogenous Antigen , 2004, Scandinavian journal of immunology.

[11]  S. Hazen,et al.  Emerging role of myeloperoxidase and oxidant stress markers in cardiovascular risk assessment , 2003, Current opinion in lipidology.

[12]  B. Fingleton.  Matrix metalloproteinase inhibitors for cancer therapy: the current situation and future prospects , 2003, Expert opinion on therapeutic targets.

[13]  E. Raines,et al.  An NF-κB-dependent Transcriptional Program Is Required for Collagen Remodeling by Human Smooth Muscle Cells* , 2003, Journal of Biological Chemistry.

[14]  F. Cambien,et al.  Plasma Concentrations and Genetic Variation of Matrix Metalloproteinase 9 and Prognosis of Patients With Cardiovascular Disease , 2003, Circulation.

[15]  I. Charo,et al.  Decreased atherosclerosis in CX3CR1-/- mice reveals a role for fractalkine in atherogenesis. , 2003, The Journal of clinical investigation.

[16]  A. Takeshita,et al.  Overexpression of matrix metalloproteinase-9 promotes intravascular thrombus formation in porcine coronary arteries in vivo. , 2003, Cardiovascular research.

[17]  E. Raines,et al.  Gene therapy of apolipoprotein E-deficient mice using a novel macrophage-specific retroviral vector. , 2003, Blood.

[18]  P. Libby,et al.  Stabilization of atherosclerotic plaques: New mechanisms and clinical targets , 2002, Nature Medicine.

[19]  C. Betsholtz,et al.  Blockade of platelet-derived growth factor or its receptors transiently delays but does not prevent fibrous cap formation in ApoE null mice. , 2002, The American journal of pathology.

[20]  Timothy C Greiner,et al.  Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. , 2002, The Journal of clinical investigation.

[21]  Jiankun Cui,et al.  S-Nitrosylation of Matrix Metalloproteinases: Signaling Pathway to Neuronal Cell Death , 2002, Science.

[22]  E. Laird,et al.  Engineering autoactivating forms of matrix metalloproteinase-9 and expression of the active enzyme in cultured cells and transgenic mouse brain. , 2002, Biochemistry.

[23]  S. Rafii,et al.  Recruitment of Stem and Progenitor Cells from the Bone Marrow Niche Requires MMP-9 Mediated Release of Kit-Ligand , 2002, Cell.

[24]  B. Marmer,et al.  Substrate Binding of Gelatinase B Induces Its Enzymatic Activity in the Presence of Intact Propeptide* , 2002, The Journal of Biological Chemistry.

[25]  Jason L Johnson,et al.  Characteristics of Intact and Ruptured Atherosclerotic Plaques in Brachiocephalic Arteries of Apolipoprotein E Knockout Mice , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[26]  E. Raines,et al.  Efficient expression of exogenous genes in primary vascular cells using IRES-based retroviral vectors. , 2002, BioTechniques.

[27]  W. Parks,et al.  Hypochlorous Acid Oxygenates the Cysteine Switch Domain of Pro-matrilysin (MMP-7) , 2001, The Journal of Biological Chemistry.

[28]  P. Libby,et al.  Expression of Neutrophil Collagenase (Matrix Metalloproteinase-8) in Human Atheroma: A Novel Collagenolytic Pathway Suggested by Transcriptional Profiling , 2001, Circulation.

[29]  L. Curtiss,et al.  Effect of &ggr;-Irradiation and Bone Marrow Transplantation on Atherosclerosis in LDL Receptor-Deficient Mice , 2001 .

[30]  C. Napoli,et al.  Spontaneous plaque rupture and secondary thrombosis in apolipoprotein E‐deficient and LDL receptor‐deficient mice , 2001, The Journal of pathology.

[31]  T. Lehtimäki,et al.  Coronary Artery Complicated Lesion Area Is Related to Functional Polymorphism of Matrix Metalloproteinase 9 Gene: An Autopsy Study , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[32]  Peter Libby,et al.  Current Concepts of the Pathogenesis of the Acute Coronary Syndromes , 2001, Circulation.

[33]  J. Crowley,et al.  Increased atherosclerosis in myeloperoxidase-deficient mice. , 2001, The Journal of clinical investigation.

[34]  Jason L. Johnson,et al.  Atherosclerotic plaque rupture in the apolipoprotein E knockout mouse. , 2001, Atherosclerosis.

[35]  Stephen M. Schwartz,et al.  Advanced Atherosclerotic Lesions in the Innominate Artery of the ApoE Knockout Mouse , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[36]  P. E. Van den Steen,et al.  Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. , 2000, Blood.

[37]  S. Shapiro,et al.  Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. , 2000, The Journal of clinical investigation.

[38]  R. Virmani,et al.  Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[39]  A. Naylor,et al.  Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption. , 2000, Stroke.

[40]  A. Luttun,et al.  Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure , 1999, Nature Medicine.

[41]  P. Libby,et al.  Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. , 1999, Circulation.

[42]  J. Sipley,et al.  Activation of Matrix Metalloproteinase-9 (MMP-9) via a Converging Plasmin/Stromelysin-1 Cascade Enhances Tumor Cell Invasion* , 1999, The Journal of Biological Chemistry.

[43]  A. Evans,et al.  Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. , 1999, Circulation.

[44]  H. Ravn,et al.  Plaque pathology and coronary thrombosis in the pathogenesis of acute coronary syndromes. , 1999, Scandinavian journal of clinical and laboratory investigation. Supplementum.

[45]  I. Charo,et al.  Decreased lesion formation in CCR2−/− mice reveals a role for chemokines in the initiation of atherosclerosis , 1998, Nature.

[46]  P. Libby,et al.  The interface of atherosclerosis and thrombosis: basic mechanisms , 1998, Vascular medicine.

[47]  P. Libby,et al.  Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. , 1998, The Journal of clinical investigation.

[48]  P. Libby,et al.  Reduction of atherosclerosis in mice by inhibition of CD40 signalling , 1998, Nature.

[49]  T Kobayashi,et al.  Expression and localization of matrix metalloproteinase-12 in the aorta of cholesterol-fed rabbits: relationship to lesion development. , 1998, The American journal of pathology.

[50]  G. Hansson,et al.  Hypercholesterolemia is associated with a T helper (Th) 1/Th2 switch of the autoimmune response in atherosclerotic apo E-knockout mice. , 1998, The Journal of clinical investigation.

[51]  R. Terkeltaub,et al.  A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. , 1998, The Journal of clinical investigation.

[52]  Christopher K. Glass,et al.  The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation , 1998, Nature.

[53]  P. Carmeliet,et al.  Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation , 1997, Nature Genetics.

[54]  D. Harrison,et al.  Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. , 1996, The Journal of clinical investigation.

[55]  S. Shapiro,et al.  Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[56]  T. Ley,et al.  Metalloelastase is required for macrophage-mediated proteolysis and matrix invasion in mice. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[57]  E. Lakatta,et al.  Increased expression of 72-kd type IV collagenase (MMP-2) in human aortic atherosclerotic lesions. , 1996, The American journal of pathology.

[58]  M J Davies,et al.  Acute coronary thrombosis--the role of plaque disruption and its initiation and prevention. , 1995, European heart journal.

[59]  M. Ferguson,et al.  Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis. , 1995, Circulation.

[60]  V. Fuster,et al.  Coronary plaque disruption. , 1995, Circulation.

[61]  J. Isner,et al.  Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. , 1995, Circulation.

[62]  P. Libby,et al.  Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. , 1994, The Journal of clinical investigation.

[63]  W. Parks,et al.  Distinct mechanisms regulate interstitial collagenase and 92-kDa gelatinase expression in human monocytic-like cells exposed to bacterial endotoxin. , 1993, The Journal of biological chemistry.

[64]  E. Falk.  Why do plaques rupture? , 1992, Circulation.

[65]  K. Naka,et al.  Matrix metalloproteinase 9 (92-kDa gelatinase/type IV collagenase) from HT 1080 human fibrosarcoma cells. Purification and activation of the precursor and enzymic properties. , 1992, The Journal of biological chemistry.

[66]  A. Henney,et al.  Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[67]  A. Eisen,et al.  Neutral metalloproteinases produced by human mononuclear phagocytes. Enzyme profile, regulation, and expression during cellular development. , 1990, The Journal of clinical investigation.

[68]  A. Eisen,et al.  SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages. , 1989, The Journal of biological chemistry.

[69]  K. Carstairs.  The identification of platelets and platelet antigens in histological sections. , 1965, The Journal of pathology and bacteriology.